The role of fragile X mental retardation protein in major mental disorders.
Fragile X mental retardation protein (FMRP) is highly enriched in neurons and binds to approximately 4% of mRNAs in mammalian brain. Its loss is a hallmark of fragile X syndrome (FXS), the most common form of mental retardation. In this review we discuss the mutation in the fragile X mental retardation-1 gene (FMR1), that leads to FXS, the role FMRP plays in neuronal cells, experiments from our own laboratory that demonstrate reductions of FMRP in additional psychiatric disorders (autism, schizophrenia, bipolar disorder, and major depressive disorder), and potential therapies to ameliorate the loss of FMRP. This article is part of a Special Issue entitled 'Trends in neuropharmacology: in memory of Erminio Costa'.
Department of Psychiatry, Division of Neuroscience Research, University of Minnesota Medical School, 420 Delaware St SE, MMC 392, Minneapolis, MN 55455, USA. fatem002@umn.edu
S Hossein
SH
Fatemi
Timothy D
TD
Folsom
D000818:Animals; D001321:Autistic Disorder / Q000235:genetics / Q000503:physiopathology; D002531:Cerebellum / Q000503:physiopathology; D005260:Female; D051860:Fragile X Messenger Ribonucleoprotein 1 / Q000235:genetics / Q000378:metabolism*; D005600:Fragile X Syndrome / Q000235:genetics / Q000378:metabolism; D006801:Humans; D008607:Intellectual Disability / Q000188:drug therapy / Q000235:genetics / Q000378:metabolism; D008297:Male; D001523:Mental Disorders / Q000188:drug therapy / Q000235:genetics / Q000378:metabolism*; D051379:Mice; D058990:Molecular Targeted Therapy
D051860:Fragile X Messenger Ribonucleoprotein 1